Martine T P Besouw1, Maria Van Dyck2, Inge Francois3, Elke Van Hoyweghen4, Elena N Levtchenko2. 1. Department of Pediatric Nephrology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. martine.besouw@uzleuven.be. 2. Department of Pediatric Nephrology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. 3. Department of Pediatric Endocrinology, University Hospitals Leuven, Leuven, Belgium. 4. Department of Pediatrics, Jessa Hospital, Hasselt, Belgium.
Abstract
BACKGROUND: Cystinosis is an autosomal recessive disorder characterized by intralysosomal cystine accumulation. Growth retardation is more pronounced in cystinosis than in other chronic kidney diseases and is mostly not corrected by cysteamine. METHODS: Growth was evaluated in nine cystinosis patients, all treated with cysteamine, both after cysteamine and recombinant human growth hormone (rhGH) therapy initiation. Growth hormone (GH) secretion was studied by nocturnal GH measurements in four of nine patients and by glucagon test in four of nine patients. RESULTS: RhGH was administered to seven of nine patients. At rhGH initiation, height was below -2 SDS in five of seven patients, final height was above -2 SDS in six of seven. In two patients not treated with rhGH, final height remained below -4 SDS despite cysteamine treatment being started at the age of 6.1 and 8.1 years, respectively. Nocturnal GH secretion was normal in all patients. Glucagon tests revealed GH deficiency in one patient; two of four patients had abnormal GH peak timing. CONCLUSIONS: We present the first reported case of GH deficiency in cystinosis. Although no overt GH deficiency was detected in other patients, abnormal GH peak timing can indicate a subclinical GH secretion problem. RhGH significantly improved growth in cystinosis patients and should be initiated early in life.
BACKGROUND:Cystinosis is an autosomal recessive disorder characterized by intralysosomal cystine accumulation. Growth retardation is more pronounced in cystinosis than in other chronic kidney diseases and is mostly not corrected by cysteamine. METHODS: Growth was evaluated in nine cystinosispatients, all treated with cysteamine, both after cysteamine and recombinant humangrowth hormone (rhGH) therapy initiation. Growth hormone (GH) secretion was studied by nocturnal GH measurements in four of nine patients and by glucagon test in four of nine patients. RESULTS:RhGH was administered to seven of nine patients. At rhGH initiation, height was below -2 SDS in five of seven patients, final height was above -2 SDS in six of seven. In two patients not treated with rhGH, final height remained below -4 SDS despite cysteamine treatment being started at the age of 6.1 and 8.1 years, respectively. Nocturnal GH secretion was normal in all patients. Glucagon tests revealed GH deficiency in one patient; two of four patients had abnormal GH peak timing. CONCLUSIONS: We present the first reported case of GH deficiency in cystinosis. Although no overt GH deficiency was detected in other patients, abnormal GH peak timing can indicate a subclinical GH secretion problem. RhGH significantly improved growth in cystinosispatients and should be initiated early in life.
Authors: M Town; G Jean; S Cherqui; M Attard; L Forestier; S A Whitmore; D F Callen; O Gribouval; M Broyer; G P Bates; W van't Hoff; C Antignac Journal: Nat Genet Date: 1998-04 Impact factor: 38.330
Authors: Georg Brabant; Alexander von zur Mühlen; Christian Wüster; Michael B Ranke; Jürgen Kratzsch; Wieland Kiess; Jean-Marie Ketelslegers; Lars Wilhelmsen; Lena Hulthén; Bernhard Saller; Anders Mattsson; Jürgen Wilde; Rudolf Schemer; Peter Kann Journal: Horm Res Date: 2003
Authors: Neveen A Soliman; Mohamed A Elmonem; Lambertus van den Heuvel; Rehab H Abdel Hamid; Mohamed Gamal; Inge Bongaers; Sandrine Marie; Elena Levtchenko Journal: JIMD Rep Date: 2014-01-25
Authors: Francesco Emma; Galina Nesterova; Craig Langman; Antoine Labbé; Stephanie Cherqui; Paul Goodyer; Mirian C Janssen; Marcella Greco; Rezan Topaloglu; Ewa Elenberg; Ranjan Dohil; Doris Trauner; Corinne Antignac; Pierre Cochat; Frederick Kaskel; Aude Servais; Elke Wühl; Patrick Niaudet; William Van't Hoff; William Gahl; Elena Levtchenko Journal: Nephrol Dial Transplant Date: 2014-09 Impact factor: 5.992
Authors: Ankana Daga; Amar J Majmundar; Daniela A Braun; Heon Yung Gee; Jennifer A Lawson; Shirlee Shril; Tilman Jobst-Schwan; Asaf Vivante; David Schapiro; Weizhen Tan; Jillian K Warejko; Eugen Widmeier; Caleb P Nelson; Hanan M Fathy; Zoran Gucev; Neveen A Soliman; Seema Hashmi; Jan Halbritter; Margarita Halty; Jameela A Kari; Sherif El-Desoky; Michael A Ferguson; Michael J G Somers; Avram Z Traum; Deborah R Stein; Ghaleb H Daouk; Nancy M Rodig; Avi Katz; Christian Hanna; Andrew L Schwaderer; John A Sayer; Ari J Wassner; Shrikant Mane; Richard P Lifton; Danko Milosevic; Velibor Tasic; Michelle A Baum; Friedhelm Hildebrandt Journal: Kidney Int Date: 2017-10-12 Impact factor: 10.612
Authors: Mohamed A Elmonem; Koenraad R Veys; Neveen A Soliman; Maria van Dyck; Lambertus P van den Heuvel; Elena Levtchenko Journal: Orphanet J Rare Dis Date: 2016-04-22 Impact factor: 4.123
Authors: Maria Helena Vaisbich; Juliana Caires Ferreira; Heather Price; Kyleen D Young; Saba Sile; Gregg Checani; Craig B Langman Journal: JIMD Rep Date: 2021-11-01